Revised SPC: Livial (tibolone) tablets

SPC now includes updated warnings regarding increased risk of breast cancer after HRT cessation, which corresponds to duration of treatment. It highlights the increased risk in users of oestrogen-only and tibolone is lower than seen in users of oestrogen-progestogen combinations.

electronic Medicines compendium